Literature DB >> 24596823

Unusual presentation of retroperitoneal leiomyosarcoma mimicking an adnexal tumor with highly elevated serum CA-19-9.

Dong Hyu Cho1, Jeong Heon Lee1, Byung Chan Oh1.   

Abstract

When retroperitoneal leiomyosarcoma develops in pelvic cavity, it often presents similar symptoms and radiological findings to adnexal tumor, therefore obscures diagnostic approaches until an exploratory laparotomy is performed. We report an unusual presentation of retroperitoneal leiomyosarcoma mimicking an adnexal tumor with extremely elevated serum CA-19-9. Though the most of the prominent mass was removed during surgery, there was massive bleeding due to tearing of internal iliac vein while dissecting the ureter close to vessels. This case focuses on the significance of considering retroperitoneal tumor even if the mass is located in ovarian fossa and has highly elevated serum level of CA-19-9. And in attempt of tumor removal, the excision needs to be clean-cut without damaging nerves or vessels around the mass and avoid causing any prospective complications.

Entities:  

Keywords:  Adnexal tumor; CA-19-9; Leiomyosarcoma; Retroperitoneal

Year:  2014        PMID: 24596823      PMCID: PMC3924737          DOI: 10.5468/ogs.2014.57.1.77

Source DB:  PubMed          Journal:  Obstet Gynecol Sci        ISSN: 2287-8572


  15 in total

1.  CT and MR imaging of leiomyosarcoma of the inferior vena cava.

Authors:  W J van Rooij; F Martens; B Verbeeten; J Dijkstra
Journal:  J Comput Assist Tomogr       Date:  1988 May-Jun       Impact factor: 1.826

Review 2.  Tumors of the retroperitoneum.

Authors:  E L Felix; D K Wood; T K Das Gupta
Journal:  Curr Probl Cancer       Date:  1981-07       Impact factor: 3.187

3.  Leiomyosarcoma: a 45-year review at Charity Hospital, New Orleans.

Authors:  M A Hill; R Mera; E A Levine
Journal:  Am Surg       Date:  1998-01       Impact factor: 0.688

4.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

Authors:  G Sutton; J A Blessing; J H Malfetano
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

5.  Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control.

Authors:  R C van Doorn; M P Gallee; A A Hart; E Gortzak; E J Rutgers; F van Coevorden; R B Keus; F A Zoetmulder
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

6.  Retroperitoneal neural sheath tumors: Cleveland Clinic experience.

Authors:  B V Guz; D P Wood; J E Montie; J E Pontes
Journal:  J Urol       Date:  1989-12       Impact factor: 7.450

7.  Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location.

Authors:  M J Kransdorf
Journal:  AJR Am J Roentgenol       Date:  1995-01       Impact factor: 3.959

Review 8.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.

Authors:  J J Lewis; D Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

9.  Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution.

Authors:  Alessandro Gronchi; Paolo G Casali; Marco Fiore; Luigi Mariani; Salvatore Lo Vullo; Rossella Bertulli; Maurizio Colecchia; Laura Lozza; Patrizia Olmi; Mario Santinami; Juan Rosai
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

10.  Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report.

Authors:  Georgios Marcouizos; Eleftheria Ignatiadou; Georgios E Papanikolaou; Dimosthenis Ziogas; Michail Fatouros
Journal:  Cases J       Date:  2009-07-30
View more
  1 in total

1.  Clinical experience with the treatment of retroperitoneal vascular leiomyosarcoma originating from large veins.

Authors:  Hong-Xian Zhang; Kai Wang; Peng Hong; Min Lu; Zhuo Liu; Lei Liu; Guo-Liang Wang; Lu-Lin Ma
Journal:  BMC Surg       Date:  2021-08-15       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.